| ²é¿´: 886 | »Ø¸´: 2 | ||
wfwsgvÌú¸Ëľ³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
¹ØÓÚÒ©Æ·ÔÚÅ·ÃËÉÏÊеÄÏà¹ØÎÊÌâ ÒÑÓÐ1È˲ÎÓë
|
|
Å·Ã˵ÄÉÏÊÐÊÚȨ³ÖÓÐÕߺÍÒ©Æ·Éú²úÕߣ¬¿ÉÒÔ²»ÊÇͬһ¼ÒÆóÒµ£¬ÄÇô£¬±ÈÈçÔÑÐÉú²ú³§¼Ò¿ÉÒÔ°Ñ×Ô¼ºÉú²úµÄ²úÆ·ÔÚÆäËüÅ·Ã˹ú¼ÒÉÏÊеÄËùÓÐȨתÂô¸øÆäËüÆóÒµ£¬ÆäËüÆóÒµ¿É·ñʹÓò»Í¬µÄÉ̱꣨°ü×°¼°ËµÃ÷Ê飩£©½øÐÐÏúÊÛ£¬µ«ÊÇÉú²ú³§¼Ò»¹ÊÇÔÑг§¼Ò£¿´Ëʱ¸ÃÖÆ¼ÁÊÇ·ñ¿ÉÒÔ×÷ΪÔÑÐÆ·À´Ê¹Óã¿ ÀýÈçÏÂÃæÕâ¶ÎÒ©Æ·Ó¢ÎÄ˵Ã÷ÊéËùÃèÊöµÄ£º Boehringer Ingelheim Limited, Consumer Healthcare, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom. Manufacturer Beaufour Ipsen Industrie, Rue Ethe Virton, 28100 Dreux, France. This medicinal product is authorised in the Member States of the EEA under the following names: Forlax 10g in Austria, Belgium, Czech Republic, Estonia, France, Latvia, Lithuania, Luxemburg, Poland, Portugal, Slovakia, and The Netherlands; Dulcolax M Balance in Germany, Tanilas 10g in Greece, Idrolax in Ireland, Paxabel 10g in Italy, and Dulcobalance in the United Kingdom |
» ²ÂÄãϲ»¶
ҩѧ¿¼Ñе÷¼Á
ÒѾÓÐ0È˻ظ´
»ªÄÏÀí¹¤´óѧ-ҽѧԺ-ҩѧר˶ÉÙÁ¿µ÷¼ÁÃû¶î
ÒѾÓÐ28È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ194È˻ظ´
ÇóÖú¡¶ÉúÎïÀûÓöȺÍÉúÎïµÈЧÐÔÑо¿Ö¸µ¼ÔÔò¡·£¨ÊÔ ÐУ©£¬2002
ÒѾÓÐ0È˻ظ´
ÎÄÏ×ÇóÖú
ÒѾÓÐ0È˻ظ´
wfwsgv
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 10256.6
- É¢½ð: 43
- ºì»¨: 1
- Ìû×Ó: 474
- ÔÚÏß: 223.9Сʱ
- ³æºÅ: 608884
- ×¢²á: 2008-09-21
- ÐÔ±ð: GG
- רҵ: ÖÐҩѧÆäËû¿ÆÑ§ÎÊÌâ
2Â¥2016-08-18 18:00:11
ÐǺ£»Û¶ù
ÈÙÓþ°æÖ÷ (Ö°Òµ×÷¼Ò)
ľ³æ¾«Áé
- DRDEPI: 17
- Ó¦Öú: 849 (²©ºó)
- ¹ó±ö: 0.978
- ½ð±Ò: 22119.4
- É¢½ð: 3714
- ºì»¨: 103
- ɳ·¢: 5
- Ìû×Ó: 3828
- ÔÚÏß: 803.1Сʱ
- ³æºÅ: 568253
- ×¢²á: 2008-06-03
- רҵ: ·ÖÎö»¯Ñ§
- ¹ÜϽ: ÐÂÒ©Ñз¢
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
wfwsgv: ½ð±Ò+1 2016-09-03 15:55:07
wfwsgv: ½ð±Ò+1 2016-09-03 15:55:38
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
wfwsgv: ½ð±Ò+1 2016-09-03 15:55:07
wfwsgv: ½ð±Ò+1 2016-09-03 15:55:38
| ËûÐèÒªÊÇÔÚͬһÉú²úÏßÉϳöÀ´µÄ£¬»¹ÐèÌṩÏà¹ØÖ¤Ã÷£¬Èô²»Êǵϰ£¬Ïë×÷Ϊ²Î±ÈÖÆ¼Á¾Í±ØÐëÄóöÖÊÁ¿ºÍÁÆÐ§ÓëÔÑÐÒ»ÖµÄÖ¤Ã÷ÐÔ×ÊÁÏ¡£Õâ¸ö¾ÍÏñ²Î±ÈÖÆ¼ÁÑ¡ÔñÖ¸µ¼ÔÔòÀïÃæµÄ½ø¿ÚÒ©ºÍµØ²úÆ·ÖÖɸѡÔÑÐʱ²î²»¶à¡£¸öÈËÀí½â |

3Â¥2016-08-19 09:12:12













»Ø¸´´ËÂ¥
5